Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K
Oral Cavity01:11

Oral Cavity

3.2K
The oral cavity, or the mouth, is a complex structure in humans that plays a vital role in our day-to-day lives. Its role is not only in chewing and swallowing food; it also plays a role in speech and facial expressions.
Teeth: The teeth are the hardest structures in our bodies. Humans have two sets of teeth throughout their lifetime: deciduous (baby) teeth and permanent teeth. Each tooth consists of several parts: the crown (visible part), the root (embedded in the jaw), enamel (hard outer...
3.2K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

693
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
693
Psychosexual Stages of Personality: Oral01:16

Psychosexual Stages of Personality: Oral

3.2K
The oral stage is the initial phase of Sigmund Freud's theory of psychosexual development, occurring from birth to approximately 12 to 18 months. During this period, the infant's mouth serves as the primary source of pleasure, with actions such as sucking, chewing, biting, and drinking playing a crucial role in reducing tension. These activities are essential not only for nourishment but also for the infant's psychological and emotional satisfaction.
Weaning, typically occurring...
3.2K
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

1.2K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Usability and feasibility of E-nergEYEze: a blended vision-specific E-health based cognitive behavioral therapy and self-management intervention to reduce fatigue in adults with visual impairment.

BMC health services research·2023
Same author

Preliminary Study on Open Labelled Randomized Controlled Trial of the Safety and Efficacy of Hydroxychloroquine and Chloroquine Phosphate for the Treatment of Persons Infected with 2019 Coronavirus Disease in Nigeria.

West African journal of medicine·2023
Same author

The effectiveness of motivational interviewing on adherence to wearing orthopedic shoes in people with diabetes at low-to-high risk of foot ulceration: A multicenter cluster-randomized controlled trial.

Diabetes research and clinical practice·2023
Same author

Attitudes and experiences towards the application of motivational interviewing by podiatrists working with people with diabetes at high-risk of developing foot ulcers: a mixed-methods study.

Journal of foot and ankle research·2022
Same author

Impact of respiratory infectious epidemics on STEMI incidence and care.

Scientific reports·2021
Same author

Using motivational interviewing combined with digital shoe-fitting to improve adherence to wearing orthopedic shoes in people with diabetes at risk of foot ulceration: study protocol for a cluster-randomized controlled trial.

Trials·2021

Related Experiment Video

Updated: Feb 12, 2026

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

8.9K

Oral anticoagulation with edoxaban.

I Ahrens, C Bode

    Hamostaseologie
    |March 29, 2018
    PubMed
    Summary
    This summary is machine-generated.

    Edoxaban, a novel oral direct factor Xa inhibitor, shows promise in preventing stroke and venous thromboembolism. Ongoing trials evaluate its efficacy in atrial fibrillation and deep vein thrombosis patients.

    More Related Videos

    Oral Biofilm Sampling for Microbiome Analysis in Healthy Children
    10:42

    Oral Biofilm Sampling for Microbiome Analysis in Healthy Children

    Published on: December 31, 2017

    17.9K
    A Standardized Approach to Extra-Oral and Intra-Oral Digital Photography
    06:49

    A Standardized Approach to Extra-Oral and Intra-Oral Digital Photography

    Published on: July 22, 2022

    10.3K

    Related Experiment Videos

    Last Updated: Feb 12, 2026

    Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
    07:08

    Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

    Published on: September 5, 2017

    8.9K
    Oral Biofilm Sampling for Microbiome Analysis in Healthy Children
    10:42

    Oral Biofilm Sampling for Microbiome Analysis in Healthy Children

    Published on: December 31, 2017

    17.9K
    A Standardized Approach to Extra-Oral and Intra-Oral Digital Photography
    06:49

    A Standardized Approach to Extra-Oral and Intra-Oral Digital Photography

    Published on: July 22, 2022

    10.3K

    Area of Science:

    • Pharmacology
    • Cardiovascular Medicine
    • Thrombosis Research

    Background:

    • Edoxaban is an orally available direct factor Xa inhibitor, developed from DX-9065a.
    • It is the third new oral anticoagulant in its class approved for preventing venous thromboembolism post-orthopaedic surgery.

    Purpose of the Study:

    • To discuss the pharmacological properties of edoxaban.
    • To review its late-stage clinical development for stroke prevention in non-valvular atrial fibrillation and venous thromboembolism treatment/prevention.

    Main Methods:

    • Phase III clinical trials: ENGAGE AF-TIMI 48 (stroke prevention in atrial fibrillation) and HOKUSAI VTE (venous thromboembolism).
    • These trials involve large patient cohorts (21,107 in ENGAGE AF-TIMI 48, planned 7,500 in HOKUSAI VTE).

    Main Results:

    • Edoxaban exhibits a time to peak plasma concentrations of 1-2 hours and a half-life of approximately 10 hours.
    • Clinical approval for venous thromboembolism prevention after major orthopaedic surgery has been obtained.

    Conclusions:

    • Edoxaban is a significant development in oral anticoagulation therapy.
    • Further data from large-scale trials will clarify its role in managing stroke and venous thromboembolism.